CHOP-Rituximab Augmented With GM-CSF in Patients With Previously Untreated Diffuse Large B Cell Non-Hodgkin's Lymphoma
Status:
Terminated
Trial end date:
2011-07-01
Target enrollment:
Participant gender:
Summary
The primary goal of this study is to determine the effects (good and bad) of
Granulocyte-macrophage colony stimulating factor (GM-CSF) in combination with Cytoxan,
Adriamycin, Vincristine, Prednisone, Rituximab (CHOP-R) on diffuse Large B cell Non-Hodgkin's
lymphoma (DLBCL). The standard of care for DLBCL is the combination of drugs known as
CHOP-Rituximab (CHOP-R). The drugs that make up CHOP-R are the chemotherapy drugs
cyclophosphamide, doxorubicin and vincristine, prednisone and rituximab. GM-CSF is a drug
that stimulates the immune system by increasing the numbers of white blood cells. Previous
research has shown that GM-CSF might help rituximab to be more effective in treating
lymphoma.
Phase:
Phase 2
Details
Lead Sponsor:
Massachusetts General Hospital
Collaborators:
Bayer Beth Israel Deaconess Medical Center Brigham and Women's Hospital Dana-Farber Cancer Institute